{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T21:48:25Z","timestamp":1761515305535,"version":"build-2065373602"},"reference-count":71,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2004,3,1]],"date-time":"2004-03-01T00:00:00Z","timestamp":1078099200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2004,3,1]],"date-time":"2004-03-01T00:00:00Z","timestamp":1078099200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["aacejournalendocrinepractice.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Endocrine Practice"],"published-print":{"date-parts":[[2004,3]]},"DOI":"10.4158\/ep.10.2.139","type":"journal-article","created":{"date-parts":[[2013,4,5]],"date-time":"2013-04-05T21:17:52Z","timestamp":1365196672000},"page":"139-148","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":28,"title":["Clinical Use of Teriparatide in the Real World: Initial Insights"],"prefix":"10.1016","volume":"10","author":[{"given":"Paul D.","family":"Miller","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John P.","family":"Bilezikian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chad","family":"Deal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Steven T.","family":"Harris","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roberto","family":"Pacifici","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.4158\/EP.10.2.139_bb0005","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1056\/NEJM200105103441904","article-title":"Effect of parathyroid hormone (1-34) on fractures and BMD in postmenopausal women with osteoporosis","volume":"344","author":"Neer","year":"2001","journal-title":"NEngl J Med."},{"key":"10.4158\/EP.10.2.139_bb0010","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1359\/jbmr.2003.18.1.9","article-title":"The effect of teriparatide [human parathyroid hormone (1-34)] therapy on bone density in men with osteoporosis","volume":"18","author":"Orwoll","year":"2003","journal-title":"J Bone Miner Res."},{"key":"10.4158\/EP.10.2.139_bb0015","doi-asserted-by":"crossref","first-page":"919","DOI":"10.7326\/0003-4819-114-11-919","article-title":"Pre-existing fracture and bone mass predict vertebral fracture incidence in women","volume":"114","author":"Ross","year":"1991","journal-title":"Ann Intern Med."},{"key":"10.4158\/EP.10.2.139_bb0020","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1001\/jama.285.3.320","article-title":"Risk of new vertebral fracture in the year following a fracture","volume":"285","author":"Lindsay","year":"2001","journal-title":"JAMA."},{"key":"10.4158\/EP.10.2.139_bb0025","doi-asserted-by":"crossref","DOI":"10.1001\/archinte.164.10.1113","article-title":"An approach of identifying osteopenic women at increased short-term risk for fracture","author":"Miller","year":"2004","journal-title":"Arch Int Med"},{"key":"10.4158\/EP.10.2.139_bb0030","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1385\/JCD:4:2:105","article-title":"The importance of precision in bone density","volume":"4","author":"Bonnick","year":"2001","journal-title":"J Clin Densitom."},{"key":"10.4158\/EP.10.2.139_bb0035","doi-asserted-by":"crossref","first-page":"29S","DOI":"10.1385\/JCD:5:3S:S29","article-title":"For the International Society for Clinical Densitometry Position Development Panel and Scientific Advisory Committee. What is the role of serial BMD measurements in patient management?","volume":"5","author":"Lenchik","year":"2002","journal-title":"J Clin Densitom"},{"key":"10.4158\/EP.10.2.139_bb0040","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1016\/S0140-6736(96)07088-2","article-title":"for the Fracture Intervention Trial Research Group. Randomized trial of effect of alendronate on risk of fracture in women with existing vertebral fractures","volume":"348","author":"Black","year":"1996","journal-title":"Lancet"},{"key":"10.4158\/EP.10.2.139_bb0045","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1001\/jama.282.14.1344","article-title":"for the Vertebral Efficacy With Risedronate Therapy (VERT) Study Group. Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial","volume":"282","author":"Harris","year":"1999","journal-title":"JAMA"},{"key":"10.4158\/EP.10.2.139_bb0050","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1007\/s001980050010","article-title":"for the Vertebral Efficacy with Risedronate Therapy (VERT) Study Group. Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis","volume":"11","author":"Reginster","year":"2000","journal-title":"Osteoporos Int"},{"key":"10.4158\/EP.10.2.139_bb0055","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1056\/NEJM200102013440503","article-title":"for the Hip Intervention Program Study Group. Effect of risedronate on the risk of hip fracture in elderly women","volume":"344","author":"McClung","year":"2001","journal-title":"N Engl J Med."},{"key":"10.4158\/EP.10.2.139_bb0060","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/S8756-3282(02)00946-8","article-title":"Longterm efficacy of risedronate: a 5-year placebo-controlled clinical experience","volume":"32","author":"Sorensen","year":"2003","journal-title":"Bone."},{"key":"10.4158\/EP.10.2.139_bb0065","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1001\/jama.282.7.637","article-title":"for the Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators. Reduction of vertebral fracture in postmenopausal women with osteoporosis treated with raloxifene. Results from a 3-year randomized clinical trial","volume":"282","author":"Ettinger","year":"1999","journal-title":"JAMA"},{"key":"10.4158\/EP.10.2.139_bb0070","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/S0002-9343(00)00490-3","article-title":"For the PROOF Study Group. A randomized trial of nasal spray salmon calcitonin in postmenopausal women with established osteoporosis: the prevent recurrence of osteoporotic fracture study","volume":"109","author":"Chesnut","year":"2000","journal-title":"Am J Med"},{"key":"10.4158\/EP.10.2.139_bb0075","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1385\/JCD:6:4:307","article-title":"Non-responders to osteoporosis therapy","volume":"6","author":"Lewiecki","year":"2003","journal-title":"J Clin Densit."},{"key":"10.4158\/EP.10.2.139_bb0080","doi-asserted-by":"crossref","first-page":"1804","DOI":"10.1172\/JCI113523","article-title":"Age and bone mass as predictors of fracture in a prospective study","volume":"81","author":"Hui","year":"1988","journal-title":"J Clin Invest."},{"key":"10.4158\/EP.10.2.139_bb0085","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1056\/NEJM199503233321202","article-title":"for the Study of Osteoporotic Fractures Research Group. Risk factors for hip fracture in white women","volume":"332","author":"Cummings","year":"1995","journal-title":"N Engl J Med."},{"key":"10.4158\/EP.10.2.139_bb0090","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1016\/S8756-3282(00)00381-1","article-title":"Risk of hip fracture according to the World Health Organization criteria for osteopenia and osteoporosis","volume":"27","author":"Kanis","year":"2000","journal-title":"Bone."},{"key":"10.4158\/EP.10.2.139_bb0095","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1007\/PL00004173","article-title":"Risk of hip fracture derived from relative risks: an analysis applied to the population of Sweden","volume":"11","author":"Kanis","year":"2000","journal-title":"Osteoporos Int."},{"key":"10.4158\/EP.10.2.139_bb0100","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1210\/jc.2002-021880","article-title":"Greater risk, greater benefit: true or false (editorial)","volume":"88","author":"Miller","year":"2003","journal-title":"J Clinical Endocrinol Metab."},{"key":"10.4158\/EP.10.2.139_bb0105","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1359\/jbmr.2003.18.1.18","article-title":"The skeletal response to teriparatide is largely independent of age, initial BMD, and prevalent vertebral fractures in postmenopausal women with osteoporosis","volume":"18","author":"Marcus","year":"2003","journal-title":"J Bone Miner Res."},{"key":"10.4158\/EP.10.2.139_bb0110","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1056\/NEJM199807303390502","article-title":"Alendronate for the prevention of glucocorticoid-induced osteoporosis","volume":"339","author":"Saag","year":"1998","journal-title":"N Engl J Med."},{"key":"10.4158\/EP.10.2.139_bb0115","doi-asserted-by":"crossref","first-page":"2309","DOI":"10.1002\/1529-0131(199911)42:11<2309::AID-ANR8>3.0.CO;2-K","article-title":"Risedronate therapy prevents corticosteroid-induced bone loss: a twelve-month, multicenter, randomized, double-blind, placebo-controlled, parallel-group study","volume":"42","author":"Cohen","year":"1999","journal-title":"Arthritis Rheum."},{"key":"10.4158\/EP.10.2.139_bb0120","doi-asserted-by":"crossref","first-page":"3S","DOI":"10.1007\/PL00014038","article-title":"Bisphosphonates for the prevention and treatment of corticosteroid-induced osteoporosis","volume":"12","author":"Miller","year":"2001","journal-title":"Osteoporos Int."},{"key":"10.4158\/EP.10.2.139_bb0125","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1172\/JCI6610","article-title":"Increased bone formation by prevention of osteoblast apoptosis with parathyroid hormone","volume":"104","author":"Jilka","year":"1999","journal-title":"J Clin Invest."},{"key":"10.4158\/EP.10.2.139_bb0130","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1007\/s00198-002-1312-0","article-title":"Daily treatment with parathyroid hormone is associated with an increase in vertebral cross-sectional area in postmenopausal women with glucocorticoid osteoporosis","volume":"14","author":"Rehman","year":"2003","journal-title":"Osteoporos Int."},{"key":"10.4158\/EP.10.2.139_bb0135","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1172\/JCI3914","article-title":"Parathyroid hormone treatment can reverse corticoid-induced osteoporosis: results of a randomized controlled clinical trial","volume":"102","author":"Lane","year":"1998","journal-title":"J Clin Invest."},{"key":"10.4158\/EP.10.2.139_bb0140","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1097\/01.SMJ.0000067661.21765.FC","article-title":"Analysis of 1-year vertebral fracture risk reduction data in treatments for osteoporosis","volume":"96","author":"Miller","year":"2003","journal-title":"South Med J."},{"key":"10.4158\/EP.10.2.139_bb0145","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/S8756-3282(03)00200-X","article-title":"Effect of raloxifene on the risk of new vertebral fracture in postmenopausal women with osteopenia or osteoporosis: a reanalysis of the Multiple Outcomes of Raloxifene Evaluation Trial","volume":"33","author":"Kanis","year":"2003","journal-title":"Bone."},{"key":"10.4158\/EP.10.2.139_bb0150","first-page":"S474","article-title":"Aledronate reduces risk of vertebral fracture in women with BMD T-scores above -2.5: results from the Fracture Intervention Trial (FIT)","volume":"17","author":"Black","year":"2002","journal-title":"J Bone Miner Res."},{"key":"10.4158\/EP.10.2.139_bb0155","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1210\/endo-129-1-421","article-title":"The anabolic effects of human parathyroid hormone (hPTH) on rat vertebral body mass are also reflected in the quality of bone, assessed by biomechanical testing: a comparison study between hPTH (1-34) and hPTH (1-84)","volume":"129","author":"Mosekilde","year":"1991","journal-title":"Endocrinology."},{"key":"10.4158\/EP.10.2.139_bb0160","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1210\/endo.132.4.8462456","article-title":"The effect of recombinant human (1-84) or synthetic (1-34) parathyroid hormone on the skeleton of adult osteopenic ovarecto- mized rats","volume":"132","author":"Kimmel","year":"1993","journal-title":"Endocrinology."},{"key":"10.4158\/EP.10.2.139_bb0165","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1136\/bmj.280.6228.1340","article-title":"Anabolic effect of human parathyroid hormone fragment on trabecular bone in involutional osteoporosis: a multicentre trial","volume":"280","author":"Reeve","year":"1980","journal-title":"BMJ."},{"key":"10.4158\/EP.10.2.139_bb0170","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1359\/jbmr.2003.18.4.769","article-title":"Bone mineral and collagen quality in humeri of ovariectomized cynomolgus monkeys given rhPTH (1-34) for 18 months","volume":"18","author":"Paschalis","year":"2003","journal-title":"J Bone Miner Res."},{"key":"10.4158\/EP.10.2.139_bb0175","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1016\/S8756-3282(01)00433-1","article-title":"Effects of human parathyroid hormone (1-34) LY333334 on bone mass, remodeling, mechanical properties of cortical bone in the first remodeling cycle in rabbits","volume":"28","author":"Mashiba","year":"2001","journal-title":"Bone."},{"key":"10.4158\/EP.10.2.139_bb0180","first-page":"1562","article-title":"On the mechanism of cancellous bone preservation in postmenopausal women with mild primary hyperparathyroidism","volume":"84","author":"Dempster","year":"1999","journal-title":"J Clin Endocrinol Metab."},{"key":"10.4158\/EP.10.2.139_bb0185","doi-asserted-by":"crossref","first-page":"1846","DOI":"10.1359\/jbmr.2001.16.10.1846","article-title":"Effects of daily treatment of parathyroid hormone on bone microarchitecture and turnover in patients with osteoporosis: a paired biopsy study","volume":"16","author":"Dempster","year":"2001","journal-title":"J Bone Miner Res."},{"key":"10.4158\/EP.10.2.139_bb0190","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1007\/978-1-4615-0651-5_17","article-title":"The effects of PTH (1-34) on bone structure and strength in ovariectomized monkeys","volume":"496","author":"Turner","year":"2001","journal-title":"Adv Exp Med Biol."},{"key":"10.4158\/EP.10.2.139_bb0195","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1359\/jbmr.2003.18.3.539","article-title":"Effects of teriparatide [recombinant human parathyroid hormone (1-34)] on cortical bone in postmenopausal women with osteoporosis","volume":"18","author":"Zanchetta","year":"2003","journal-title":"J Bone Miner Res."},{"key":"10.4158\/EP.10.2.139_bb0200","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1359\/jbmr.2002.17.7.1139","article-title":"Risedronate preserves trabecular architecture and increases bone strength in vertebrae of ovarectomized minipigs as measured three-dimensional microcomputed tomography","volume":"17","author":"Borah","year":"2002","journal-title":"J Bone Miner Res."},{"key":"10.4158\/EP.10.2.139_bb0205","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1359\/jbmr.2003.18.2.383","article-title":"Determinants of bone strength","volume":"18","author":"Kiebzak","year":"2003","journal-title":"J Bone Miner Res."},{"key":"10.4158\/EP.10.2.139_bb0210","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1016\/S8756-3282(02)00869-4","article-title":"Effects of long-term risedronate on bone quality and bone turnover in women with postmenopausal osteoporosis","volume":"31","author":"Eriksen","year":"2002","journal-title":"Bone."},{"key":"10.4158\/EP.10.2.139_bb0215","unstructured":"Dobnig H, et al. Early changes in biochemical markers of bone formation predict improvements in bone structure during terparatide therapy. Program & Abstracts The Endocrine Society\u2019s 85th Annual Meeting June 19-22, 2003 #OR54-2, p. 131."},{"key":"10.4158\/EP.10.2.139_bb0220","unstructured":"Krege JH, et al. Increases in serum-terminal propeptide of type I collagen with teriparatide treatment predict increases in lumbar spine bone density. Program & Abstracts The Endocrine Society\u2019s 85th Annual Meeting June 19-22, 2003 Abstract #P2-503, p. 429-430."},{"key":"10.4158\/EP.10.2.139_bb0225","doi-asserted-by":"crossref","first-page":"1342","DOI":"10.1359\/jbmr.2003.18.7.1342","article-title":"Vitamin D depletion and effective calcium absorption","volume":"18","author":"Heaney","year":"2003","journal-title":"J Bone Miner Res."},{"key":"10.4158\/EP.10.2.139_bb0230","doi-asserted-by":"crossref","first-page":"5348","DOI":"10.1210\/jc.2003-031014","article-title":"\u201cIncipient\u201d primary hyperparathyroidism: a \u201cforme fruste\u201d of an old disease","volume":"88","author":"Silverberg","year":"2003","journal-title":"J Clin Endocrinol Metab."},{"key":"10.4158\/EP.10.2.139_bb0235","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1210\/jcem.85.1.6267","article-title":"Antifracture efficacy of anti- resorptive agents are related to changes in bone density","volume":"85","author":"Wasnich","year":"2001","journal-title":"J Clin Endocrinol Metab."},{"key":"10.4158\/EP.10.2.139_bb0240","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/S0002-9343(01)01124-X","article-title":"Improvements in spine bone density and reduction in risk of vertebral fractures during treatment with antiresorptive drugs","volume":"112","author":"Cummings","year":"2002","journal-title":"Am J Med."},{"key":"10.4158\/EP.10.2.139_bb0245","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.1210\/jcem.87.4.8415","article-title":"Changes in bone density and turnover explain the reductions in incidence of nonvertebral fractures that occur during treatment with antiresorptive agents","volume":"87","author":"Hochberg","year":"2002","journal-title":"J Clin Endocrinol Metab."},{"key":"10.4158\/EP.10.2.139_bb0250","doi-asserted-by":"crossref","first-page":"1867","DOI":"10.1210\/jcem.84.6.5710","article-title":"Bone densitometry: the best way to detect osteoporosis and to monitor therapy","volume":"84","author":"Miller","year":"1999","journal-title":"J Clin Endocrinol Metab."},{"key":"10.4158\/EP.10.2.139_bb0255","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1210\/jc.2003-030501","article-title":"The impact of monitoring on adherence and persistence with antiresorptive treatment for postmenopausal osteoporosis: a randomized controlled trial","volume":"89","author":"Clowes","year":"2004","journal-title":"J Clin Endocrinol Metab."},{"key":"10.4158\/EP.10.2.139_bb0260","doi-asserted-by":"crossref","first-page":"1796","DOI":"10.1002\/jbmr.5650101124","article-title":"Comparisons of rates of bone loss from the spine measuring bone from two manufacturers densitometers","volume":"10","author":"Peel","year":"1995","journal-title":"J Bone Miner Res."},{"key":"10.4158\/EP.10.2.139_bb0265","first-page":"139S","article-title":"Teriparatide (rhPTH 1-34) Improves the structural geometry of the hip","volume":"17","author":"Uusi-Rasi","year":"2002","journal-title":"J Bone Miner Res."},{"key":"10.4158\/EP.10.2.139_bb0270","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1359\/jbmr.2003.18.6.1051","article-title":"Relationship of early changes in bone resorption to the reduction in fracture risk with risedronate","volume":"18","author":"Eastell","year":"2003","journal-title":"J Bone Miner Res."},{"key":"10.4158\/EP.10.2.139_bb0275","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1359\/jbmr.2002.17.1.11","article-title":"Bone turnover matters: the raloxifene treatment paradox of dramatic decreases in vertebral fractures without commensurate increases in bone density","volume":"17","author":"Riggs","year":"2002","journal-title":"J Bone Miner Res."},{"key":"10.4158\/EP.10.2.139_bb0280","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1385\/JCD:2:3:323","article-title":"Practical clinical application of biomarkers of bone turnover: consensus of an expert panel","volume":"2","author":"Miller","year":"1999","journal-title":"J Clin Densitom."},{"key":"10.4158\/EP.10.2.139_bb0285","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1007\/s001980170020","article-title":"Six- and twelve-month changes in bone turnover are related to reduction in vertebral fracture risk during 3 years of raloxifene treatment in postmenopausal osteoporosis","volume":"12","author":"Bjarnason","year":"2001","journal-title":"Osteoporos. Int."},{"key":"10.4158\/EP.10.2.139_bb0290","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/S0749-0690(02)00074-5","article-title":"The anabolic effects of parathyroid hormone therapy","volume":"19","author":"Rubin","year":"2003","journal-title":"Clin GeriatrMed."},{"key":"10.4158\/EP.10.2.139_bb0295","first-page":"3069","article-title":"Parathyroid hormone as a therapy for idiopathic osteoporosis in men: effects on BMD and bone markers","volume":"85","author":"Kurland","year":"2000","journal-title":"J Clin Endocrinol Metab."},{"key":"10.4158\/EP.10.2.139_bb0300","first-page":"162S","article-title":"Incident vertebral fractures during an 18-month observation period following discontinuation of LY333334 [recombinant human parathyroid hormone (91-34) rhPTH (1-34)] use in postmenopausal women with osteoporosis","volume":"16","author":"Lindsay","year":"2001","journal-title":"J Bone Miner Res."},{"key":"10.4158\/EP.10.2.139_bb0305","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1016\/S0140-6736(97)02342-8","article-title":"Randomised controlled study of the effect of parathyroid hormone on vertebral bone-mass and fracture incidence among postmenopausal women on estrogen with osteoporosis","volume":"350","author":"Lindsay","year":"1997","journal-title":"Lancet."},{"key":"10.4158\/EP.10.2.139_bb0310","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1359\/jbmr.2000.15.5.944","article-title":"Bone mass continues to increase at the hip after parathyroid hormone treatment is discontinued in glucocorticoid-induced osteoporosis: results of a randomized controlled clinical trial","volume":"15","author":"Lane","year":"2000","journal-title":"J Bone Miner Res."},{"key":"10.4158\/EP.10.2.139_bb0315","first-page":"S515","article-title":"Early response of bone turnover markers and BMD to teriparatide [recombinant human parathyroid hormone (1-34)] in postmenopausal women previously treated with an antiresorptive drug","volume":"18","author":"Ettinger","year":"2003","journal-title":"J Bone Miner Res."},{"key":"10.4158\/EP.10.2.139_bb0320","first-page":"368","article-title":"Mineral binding affinities of bisphosphonates","volume":"17","author":"Nancollas","year":"2002","journal-title":"J Bone Miner Res."},{"key":"10.4158\/EP.10.2.139_bb0325","first-page":"37","article-title":"Effects of rise- dronate discontinuation on bone turnover and bone mineral density in postmenopausal women with osteoporosis","volume":"7","author":"Watts","year":"2004","journal-title":"J Clin Densitom."},{"key":"10.4158\/EP.10.2.139_bb0330","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1056\/NEJMoa031975","article-title":"for the PaTH Study Investigators. The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosis","volume":"349","author":"Black","year":"2003","journal-title":"N Engl J Med."},{"key":"10.4158\/EP.10.2.139_bb0335","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1056\/NEJMoa035725","article-title":"The effects of parathyroid hormone, alendronate, or both in men with osteoporosis","volume":"349","author":"Finkelstein","year":"2003","journal-title":"N Engl J Med."},{"key":"10.4158\/EP.10.2.139_bb0340","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1359\/jbmr.2001.16.5.925","article-title":"Parathyroid hormone added to established hormone therapy: effects on vertebral fracture and maintenance of bone mass after parathyroid hormone withdrawal","volume":"16","author":"Cosman","year":"2001","journal-title":"J Bone Miner Res."},{"key":"10.4158\/EP.10.2.139_bb0345","doi-asserted-by":"crossref","unstructured":"Hodsman AB, Hanley DA, Ettinger MP, et al. Efficacy and safety of human parathyroid hormone (1-84) in increasing BMD in postmenopausal osteoporosis. J Clin Endocrinol Metab. 2003;88:(in press).","DOI":"10.1210\/jc.2003-030768"},{"key":"10.4158\/EP.10.2.139_bb0350","first-page":"2129","article-title":"Enhancement of bone mass in osteoporotic women with parathyroid hormone followed by alendronate","volume":"85","author":"Rittmaster","year":"2000","journal-title":"J Clin Endocrinol Metab."},{"key":"10.4158\/EP.10.2.139_bb0355","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1359\/jbmr.2003.18.1.163","article-title":"Osteosarcoma of bone in a patient with primary hyperparathyroidism: a case report","volume":"18","author":"Betancourt","year":"2003","journal-title":"Bone Miner Res."}],"container-title":["Endocrine Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1530891X20401636?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1530891X20401636?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/aace.metapress.com\/index\/5C9MC6CL3VA94ADE.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T21:44:49Z","timestamp":1761515089000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1530891X20401636"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,3]]},"references-count":71,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2004,3]]}},"alternative-id":["S1530891X20401636"],"URL":"https:\/\/doi.org\/10.4158\/ep.10.2.139","relation":{},"ISSN":["1530-891X"],"issn-type":[{"type":"print","value":"1530-891X"}],"subject":[],"published":{"date-parts":[[2004,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Clinical Use of Teriparatide in the Real World: Initial Insights","name":"articletitle","label":"Article Title"},{"value":"Endocrine Practice","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.4158\/EP.10.2.139","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2004 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}